Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) PT at $19.73

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been given a consensus rating of “Hold” by the thirteen ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $19.7273.

BCYC has been the topic of a number of recent analyst reports. JMP Securities set a $12.00 price target on Bicycle Therapeutics in a report on Friday, October 31st. Royal Bank Of Canada reiterated a “sector perform” rating and set a $11.00 target price (down previously from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Citizens Jmp boosted their price target on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Finally, Truist Financial initiated coverage on shares of Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 price objective on the stock.

Insider Buying and Selling

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $8.41, for a total transaction of $27,172.71. Following the completion of the transaction, the chief executive officer owned 475,310 shares of the company’s stock, valued at $3,997,357.10. This represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 8,527 shares of company stock valued at $71,738. 8.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Several large investors have recently made changes to their positions in the company. Long Focus Capital Management LLC lifted its position in shares of Bicycle Therapeutics by 138.2% in the first quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock worth $10,984,000 after buying an additional 750,661 shares in the last quarter. Acadian Asset Management LLC increased its stake in Bicycle Therapeutics by 454.1% in the 2nd quarter. Acadian Asset Management LLC now owns 698,501 shares of the company’s stock worth $4,840,000 after acquiring an additional 572,439 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Bicycle Therapeutics by 21.7% during the 1st quarter. Armistice Capital LLC now owns 2,672,000 shares of the company’s stock worth $22,685,000 after acquiring an additional 476,000 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Bicycle Therapeutics by 64.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock valued at $8,889,000 after acquiring an additional 451,135 shares during the last quarter. Finally, Tybourne Capital Management HK Ltd. grew its holdings in shares of Bicycle Therapeutics by 72.4% in the second quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock valued at $6,907,000 after purchasing an additional 417,400 shares in the last quarter. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Price Performance

Shares of NASDAQ:BCYC opened at $6.80 on Friday. The company has a market capitalization of $471.70 million, a P/E ratio of -1.88 and a beta of 1.47. Bicycle Therapeutics has a 1-year low of $6.03 and a 1-year high of $15.47. The firm’s 50 day simple moving average is $7.09 and its two-hundred day simple moving average is $7.45.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.24. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. The firm had revenue of $11.73 million during the quarter, compared to analysts’ expectations of $8.25 million. On average, sell-side analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.